Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Satricabtagene autoleucel - CARsgen

Next Previous
Drug Profile

Satricabtagene autoleucel - CARsgen

Alternative Names: 1-3 CT041 autologous CAR T-cell injection infusion; Anti-Claudin18.2-CAR-T cell therapy - CARsgen; CAR-CLD18 T cell therapy - CARsgen; CAR-CLDN18.2 T-Cells; Chimeric Antigen Receptor T cells targeting Claudin18.2; Claudin 18.2-CAR-T cell therapy - CARsgen; Claudin18.2 (CLDN18.2) CAR-T - CARsgen; Claudin18.2-redirected Autologous Cells - CARsgen; CLD18-CAR-T cell therapy - CARsgen; CLDN18.2 targeting CAR-T cell therapy - CARsgen; CT-041; CT041 autologous CAR T-cell injection; satri-cel

Latest Information Update: 01 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CARsgen
  • Developer CARsgen; Peking University
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Oesophageal cancer
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Adenocarcinoma
  • Phase II Gastric cancer; Oesophageal cancer; Pancreatic cancer

Most Recent Events

  • 25 Jun 2025 Preregistration for Adenocarcinoma (Adjuvant therapy, Second-line therapy or greater) in China (IV)
  • 30 May 2025 Updated adverse events data from a phase I/II trial in Gastric cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 28 May 2025 Satricabtagene autoleucel receives priority review status for Adenocarcinoma in China

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top